Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 69.25 GBp
Change Today +0.25 / 0.36%
Volume 470.9K
As of 6:39 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

vernalis plc (VER) Snapshot

69.25 GBp
Previous Close
69.00 GBp
Day High
69.25 GBp
Day Low
69.25 GBp
52 Week High
06/10/15 - 74.00 GBp
52 Week Low
07/14/14 - 31.00 GBp
Market Cap
Average Volume 10 Days
-0.0060 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VERNALIS PLC (VER)

Related News

No related news articles were found.

vernalis plc (VER) Related Businessweek News

No Related Businessweek News Found

vernalis plc (VER) Details

Vernalis plc, a research and development stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Frovatriptan, a selective 5-HT1B/1D receptor agonist for an acute oral treatment of migraine headache and its associated symptoms. The company also has a development and licensing agreement to develop approximately six extended-release liquid formulations of short-acting prescription cough cold products. In addition, it is developing V158866, a fatty acid amide hydrolase inhibitor that is in Phase II proof-of-concept (POC) clinical trial for the treatment of various pain and other CNS disorders; and V81444, an adenosine A2A receptor antagonist, which is in Phase Ib/II POC clinical trial for the treatment of Parkinson’s disease and other neurological disorders. Further, the company is developing AUY922, an intravenous Hsp90 inhibitor for treating a range of cancers in Phase I and Phase II clinical trial; CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukaemia and myelodysplastic syndrome under Phase II trial; V158411 molecule and Servier 1, which are in pre-clinical stage for treating cancer; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc; Genentech Inc; H. Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc; Novartis Pharma AG; Servier Research Group; Taisho Pharmaceutical Co., Ltd.; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.

Founded in 1988

vernalis plc (VER) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 610.0K GBP
Chief Financial Officer and Director
Total Annual Compensation: 417.0K GBP
Compensation as of Fiscal Year 2013.

vernalis plc (VER) Key Developments

Vernalis plc Appoints Ian David Gilham as Non-Executive Director and Chairman of Remuneration Committee, with Effect from 1 July 2015

Vernalis plc announced that Ian David Gilham has been appointed to the board as a Non-Executive Director with effect from 1 July 2015. Gilham will also serve as chairman of the company's remuneration committee. He also previously worked at GlaxoSmithKline as Vice President at Pharmacogenetics and before that held international general management, marketing business development and R&D positions with Abbott Laboratories, Celltech and Amersham.

Vernalis plc and Tris Pharma Inc. Receive FDA Approval of NDA for Tuzistra™ XR

Vernalis plc and Tris Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III). Tuzistra XR is an extended-release oral suspension combination of codeine, an opiate agonist antitussive, and chlorpheniramine, a histamine-1(H1) receptor antagonist, indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults aged 18 years and older. It is indicated for oral use, with or without food, and is to be dosed every 12 hours. Tuzistra XR is the only codeine based extended-release oral suspension cough-cold treatment in a U.S. prescription cough cold market which sees 30-35 million prescriptions written each year and is estimated to be worth in excess of $3 billion. Currently available short-acting codeine based cough cold treatments account for approximately 38% of that market. Tuzistra XR has been developed using Tris Pharma Inc.'s LiquiXR™ technology.

Vernalis plc - Special Call

To discuss the approval of the new drug application for Tuzistra XR extended-release oral suspension, CIII by U.S. Food and Drug Administration


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VER:LN 69.25 GBp +0.25

VER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.137.50 CHF 0.00
Endo International PLC $82.02 USD +1.13
Impax Laboratories Inc $46.31 USD -0.34
Medicines Co/The $31.28 USD +2.94
UCB SA €65.94 EUR -0.73
View Industry Companies

Industry Analysis


Industry Average

Valuation VER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.8x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERNALIS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at